Pediatrik Hastalarda Endokrin Pankreas Hastalıkları
Özet
Pankreas, sindirim enzimleri üreten ekzokrin bölümü ve kan şekerini düzenleyen hormonların salgılandığı Langerhans adacıklarından oluşan endokrin bölümüyle hayati bir organdır. Bu adacıklardaki beta hücreleri insülin, alfa hücreleri ise glukagon üreterek glukoz dengesini zıt yönlü etkilerle sağlar. Pediatrik hastalarda endokrin pankreas hastalıkları temel olarak hipoinsülinizm ve hiperinsülinizm başlıkları altında incelenir. Çocukluk çağının en yaygın endokrin bozukluğu olan Tip 1 Diyabetes Mellitus (T1DM), beta hücrelerinin otoimmün yıkımı sonucu gelişen insülin eksikliği ile karakterizedir ve mutlak insülin tedavisi ile yaşam tarzı değişikliği gerektirir. T1DM tanısı, yüksek açlık kan şekeri, semptomatik hiperglisemi veya yüksek HbA1C değerleriyle konulurken; tedavi sürecinde kan şekeri kontrolü ve komplikasyonların önlenmesi hedeflenir. Öte yandan, yenidoğanlarda kalıcı hipogliseminin en sık nedeni olan Hiperinsülinizm (Hİ), kontrolsüz insülin salınımı nedeniyle beyin hasarına yol açabilen ciddi bir durumdur. Özellikle genetik mutasyonların rol oynadığı Konjenital Hiperinsülinizmde erken teşhis ve diazoksit gibi ilaçlarla müdahale, nörogelişimsel prognoz açısından kritiktir. Her iki durum da çocuklarda metabolik dengenin korunması için multidisipliner bir yaklaşım ve titiz bir takip süreci gerektirmektedir.
The pancreas is a vital organ consisting of an exocrine part that produces digestive enzymes and an endocrine part containing the islets of Langerhans, where hormones regulating blood sugar are secreted. Within these islets, beta cells produce insulin and alpha cells produce glucagon, maintaining glucose balance through antagonistic effects. Endocrine pancreatic diseases in pediatric patients are primarily examined under the headings of hypoinsulinism and hyperinsulinism. Type 1 Diabetes Mellitus (T1DM), the most common endocrine disorder of childhood, is characterized by insulin deficiency resulting from the autoimmune destruction of beta cells and requires absolute insulin therapy along with lifestyle modifications. While T1DM is diagnosed through high fasting blood glucose, symptomatic hyperglycemia, or elevated HbA1C levels, the treatment process aims for blood sugar control and prevention of complications. On the other hand, Hyperinsulinism (HI), the most frequent cause of persistent hypoglycemia in newborns, is a serious condition that can lead to brain damage due to unregulated insulin secretion. In Congenital Hyperinsulinism, where genetic mutations play a significant role, early diagnosis and intervention with medications such as diazoxide are critical for neurodevelopmental prognosis. Both conditions require a multidisciplinary approach and a meticulous follow-up process to maintain metabolic balance in children.
Referanslar
Klingensmith GJ, Tamborlane WV, Wood J, et al. Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth. J Pediatr 2013;162:330.
Chiang JL, Kirkman MS, Laffel LM, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37:2034.
American Diabetes Association. 12. Children and Adolescents: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41:S126.
Antenor-Dorsey JA, Meyer E, Rutlin J, et al. White matter microstructural integrity in youth with type 1 diabetes. Diabetes 2013;62:581.
Peters A, Laffel L, American Diabetes Association Transitions Working Group. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetescare systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society). Diabetes Care 2011;34:2477.
Clarke WL, Cox DJ, Gonder-Frederick LA, Kovatchev B. Hypoglycemia and the decision to drive a motor vehicle by persons with diabetes. JAMA 1999;282:750.
Barnea-Goraly N, Raman M, Mazaika P, et al. Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care 2014;37:332. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159.
Stanley CA. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders. J Clin Endocrinol Metab 2016; 101:815.9. McKinlay CJD, Chase JG, Dickson J, et al. Continuous glucose monitoring in neonates: a review. Matern Health Neonatol Perinatol 2017; 3:18.
Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr 2015; 167:238.
Shah R, Harding J, Brown J, McKinlay C. Neonatal Glycaemia and Neurodevelopmental Outcomes: A Systematic Review and Meta-Analysis. Neonatology. 2019;115(2):116-126. Demirbilek H, Hussain K. Congenital hyperinsulinism: diagnosis and treatment update. JClin Res Pediatr Endocrinol. 2017;9:69–87.
Lord K, Dzata E, Snider KE, Gallagher PR, De León DD. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab. 2013 Nov;98(11):E1786-9.
